# A Study of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model in Healthy Adult Participants

> **NCT04480736** · PHASE2 · WITHDRAWN · sponsor: **Janssen Research & Development, LLC**

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Placebo
- **DRUG:** JNJ-64281802 High dose
- **DRUG:** JNJ-64281802 Medium dose
- **DRUG:** JNJ-64281802 Low dose
- **DRUG:** JNJ-64281802 Dosing Regimen X
- **DRUG:** JNJ-64281802 Dosing Regimen Y
- **DRUG:** JNJ-64281802 Dosing Regimen Z

## Key facts

- **NCT ID:** NCT04480736
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-07-28
- **Primary completion:** 2027-09-02
- **Final completion:** 2027-12-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** portfolio reprioritization
- **Last updated:** 2025-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04480736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04480736, "A Study of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model in Healthy Adult Participants". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04480736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*